Skip to main content

Januvia Disease Interactions

There are 4 disease interactions with Januvia (sitagliptin).

Moderate

DPP-4 (applies to Januvia) renal dysfunction

Moderate Potential Hazard, High plausibility.

It is recommended to assess renal function prior to initiating treatment with DPP-4 inhibitors and periodically thereafter. Patients with moderate to severe renal insufficiency and end stage renal dysfunction will require a dose adjustment. Linagliptin will not require a dose adjustment per manufacturer's information. Additionally, there have been postmarketing reports of worsening renal function in some patients with renal insufficiency taking sitagliptin at inappropriate doses.

References (4)
  1. (2006) "Product Information. Januvia (sitagliptin)." Merck & Co., Inc
  2. (2009) "Product Information. Onglyza (saxagliptin)." Bristol-Myers Squibb
  3. (2011) "Product Information. Tradjenta (linagliptin)." Boehringer Ingelheim
  4. (2013) "Product Information. Nesina (alogliptin)." Takeda Pharmaceuticals America
Moderate

DPP-4 inhibitors (applies to Januvia) pancreatitis

Moderate Potential Hazard, Low plausibility.

There have been postmarketing reports of acute pancreatitis in patients taking DPP-4 inhibitors. These drugs should be used with caution in patients with a history of pancreatitis or pancreatic disease, although it is unknown if they are at increased risk. Patients should be observed for signs and symptoms of pancreatitis during treatment. If pancreatitis is suspected, treatment should be discontinued immediately and appropriate management should be initiated.

References (4)
  1. (2006) "Product Information. Januvia (sitagliptin)." Merck & Co., Inc
  2. (2009) "Product Information. Onglyza (saxagliptin)." Bristol-Myers Squibb
  3. (2011) "Product Information. Tradjenta (linagliptin)." Boehringer Ingelheim
  4. (2013) "Product Information. Nesina (alogliptin)." Takeda Pharmaceuticals America
Moderate

Sitagliptin (applies to Januvia) heart failure

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Congestive Heart Failure, Renal Dysfunction

Consider the risks and benefits of sitagliptin prior to initiating treatment in patients at risk for heart failure, such as those with a prior history of heart failure and a history of renal impairment. Observe these patients for signs and symptoms of heart failure during therapy.

References (1)
  1. (2025) "Product Information. Sitagliptin (SITagliptin)." Zydus Pharmaceuticals (USA) Inc
Moderate

Sitagliptin (applies to Januvia) liver dysfunction

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Sitagliptin has not been studied in patients with severe liver dysfunction

References (1)
  1. (2025) "Product Information. Sitagliptin (SITagliptin)." Zydus Pharmaceuticals (USA) Inc

Switch to consumer interaction data

Januvia drug interactions

There are 295 drug interactions with Januvia (sitagliptin).

Januvia alcohol/food interactions

There is 1 alcohol/food interaction with Januvia (sitagliptin).


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.